2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150CJC-1295 No DAC (GHRH analog) and ipamorelin (GHS-R1a agonist) stimulate endogenous GH through complementary cAMP and Ca²⁺ signaling pathways.
Clinical and mechanistic studies of GHRH+GHS-R1a agonists co-administration demonstrate amplified pulsatile GH release compared to either pathway alone, supporting dual-axis activation of the somatotroph system.
CJC-1295 without DAC is a synthetic analog of growth hormone–releasing hormone (GHRH amino acid 1–29 or Mod GHF1-29 ). This CJC-1295 is designed to stimulate endogenous growth hormone (GH) secretion through activation of the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs.
Without the Drug Affinity Complex (DAC), it does not bind albumin, resulting in a shorter half-life and more physiologic, pulse-like GH stimulation.
Mechanistically, it activates the adenylyl cyclase–cAMP–protein kinase A (PKA) signaling cascade, promoting GH release and downstream increases in circulating insulin-like growth factor-1 (IGF-1) [1].
Because it works upstream at the hypothalamic–pituitary axis, CJC-1295 without DAC preserves endogenous inhibitory feedback regulation via somatostatin and IGF-1.
Ipamorelin is a selective growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHS-R1a) on anterior pituitary somatotrophs [2].
It stimulates endogenous GH release primarily through activation of the phospholipase C (PLC)–IP3–calcium signaling pathway, increasing intracellular calcium and promoting pulsatile GH secretion [3].
Unlike earlier GHS compounds and ghrelin itself, ipamorelin is relatively selective for GH release, with minimal stimulation of ACTH, cortisol, or hunger compared to less selective secretagogues [2].
By acting through a pathway distinct from GHRH analogs, ipamorelin is frequently studied in combination paradigms evaluating complementary stimulation of the somatotroph axis.
CJC-1295 without DAC and ipamorelin stimulate endogenous growth hormone (GH) release through distinct but convergent regulatory pathways within the HPA axis.
Their combined use is based on dual activation of GHRH and ghrelin receptor systems via:
Because these pathways operate independently, their combined activation should increase both the magnitude and efficiency of GH pulsatility.
Although published studies typically evaluate GHRH combined with GHRP compounds (such as GHRP-6 or ghrelin) rather than ipamorelin specifically, the mechanistic framework likely applies to ipamorelin due to its selective GHS-R1a agonism.
Cell-based studies demonstrate that co-activation of GHRH and GHS receptors can produce approximately twofold greater cAMP signaling compared to GHRH alone, suggesting receptor-level cross-talk and amplification of somatotroph responsiveness [4].
A clinical study evaluated whether ghrelin, the endogenous ligand for the GHS receptor, interacts synergistically with growth hormone–releasing hormone (GHRH) to stimulate GH secretion [5].
8 male adults were administered ghrelin (0.08, 0.2, and 1.0 μg/kg) intravenously alone or combined with 1.0 μg/kg GHRH. Results showed that combined administration with GHRH:
This study demonstrates that co-administration of ghrelin and GHRH produces true synergistic GH release in humans, exceeding additive stimulation from either agent alone.
The findings support the concept that dual activation of the GHRH receptor and GHS receptor enhances pituitary somatotroph responsiveness.
In some metabolic conditions (e.g., obesity-associated blunting of GHRH response), GHS agonists partially restored GH responsiveness [6].
Ipamorelin is highlighted in research contexts due to its relative selectivity for GH release, with minimal stimulation of ACTH and cortisol compared to earlier GHRP compounds.
This selective profile may allow more targeted evaluation of somatotroph activation without broader pituitary axis activation.
When paired with a short-acting GHRH analog such as CJC-1295 without DAC, the goal is typically to:
The absence of the DAC component in CJC-1295 results in a shorter half-life, aligning more closely with natural episodic GH dynamics rather than prolonged elevation.
Balanced ratios such as 2 mg + 2 mg or 5 mg + 5 mg can be conceptually described as targeting simultaneous engagement of:
Proportional dosing may theoretically promote coordinated receptor activation. However, precise optimization of dose ratios has not been definitively established in controlled combination trials and remains an empirical parameter in research settings.
References:
1 Sackmann-Sala, L., Ding, J., Frohman, L. A. and Kopchick, J. J. (2009) Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm. IGF Res., Elsevier BV 19, 471–477
2 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., et al. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., Oxford University Press (OUP) 139, 552–561
3 Mear, Y., Enjalbert, A. and Thirion, S. (2013) GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci., Frontiers Media SA 7, 87
4 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582
5 Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., et al. (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 4552
6 Popovic, V., Damjanovic, S., Micic, D., Djurovic, M., Dieguez, C. and Casanueva, F. F. (1995) Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab., The Endocrine Society 80, 942–947
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC-1295 (no DAC)+Ipamorelin (5+5) is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
Research-grade compound with certificate of analysis. Full analytical testing on every lot.
What is epitalon peptide? Epitalon, also known as Epithalone or Epithalon, is a synthetic tetrapeptide (Ala–Glu–Asp–Gly) derived from a naturally occurring pineal gland extract (epithalamin) [1]. Structurally, epitalon mimics endogenous peptides that influence the activity of telomerase, the enzyme responsible for maintaining telomere length. Epitalon may also modulate oxidative stress regulation, circadian rhythm stabilization, and neuroendocrine function. Epitalon peptide benefits Anti-aging and longevity One of the most widely studied aspects of epitalon is its potential influence on cellular aging through multiple biochemical pathways. A cell study investigated whether Epithalon can influence two processes central to dementia, cholinesterase activity and the formation of the soluble form of amyloid precursor protein (sAPP) in human neuroblastoma (SH-SY5Y) cells [2]. Results showed that Epithalon: Reduced excessive cholinesterase enzymatic activity. Increased sAPP formation, which is protective against Alzheimer’s-type pathology. These effects suggest that epitalon may delay or prevent mechanisms underlying conditions like Alzheimer’s disease. Similar anti-aging effects are also seen in other tissues, such as in the prevention of age-based pigmentary retinal dystrophy in genetically predisposed rats [3]. Antioxidant Oxidative stress is a central contributor to cellular aging and carcinogenesis, as unmanaged oxidative species can damage lipids, proteins, and DNA. Epitalon can mitigate such damages by enhancing endogenous antioxidant defenses. In a fruit fly study, synthetic Epithalon’s antioxidant activities were compared with the crude pineal extract, epithalamin [4]. Epitalon was added to larval nutrient medium at 0.00001 wt%, while epithalamin was added at concentrations 1000-fold higher. Epitalon addition resulted in: 20% Increased catalase activity (p<0.05) 20-50% decreased CHP content (marker of lipid peroxidation) (p<0.05) ~1000-fold higher biological activity than epithalamin Anticarcinogenic A study evaluated the effect of epitalon on tumor development and oncogene expression in 80 transgenic HER-2/neu mice, a model predisposed to breast cancer and accelerated aging [5]. Mice were either given saline as negative control, Vilon as a positive control, or Epithalon (1 µg, subcutaneous) for 5 consecutive days monthly. Results showed that epitalon: Delayed first tumor appearance by 38 days compared to Vilon, and by 20 days compared to saline. Reduced recurring tumor incidence: 28% remained tumor-free vs.18% (saline). Lowered tumor multiplicity: only 56% had ≥2 tumors vs. 75% (saline). Reduced maximum tumor diameter by 33% (p<0.05). 3.7-fold lower HER-2/neu mRNA expression compared to saline (p<0.001), whereas Vilon produced a 1.97-fold lower HER-2/neu expression. Telomere protection A defining feature of epitalon is its reported influence on telomerase activity. Telomerase is the ribonucleoprotein enzyme responsible for elongating telomeric DNA, maintaining chromosomal stability. In most somatic cells, telomerase activity is repressed, which leads to progressive telomere shortening during replication. When telomeres become critically short, cells enter senescence, a hallmark of aging [6]. An in vitro study evaluated whether epitalon can activate telomerase and elongate telomeres in human somatic cells [7]. Human fetal fibroblasts were exposed to epitalon at varying concentrations, resulting in: Increased telomerase Telomere elongation Extended proliferative capacity beyond the normal Hayflick limit (40-60 replications before senescence and death) Circadian rhythm Epitalon has been linked to pineal gland regulation through melatonin, a hormone that regulates sleep–wake cycles and seasonal biological rhythms. Melatonin naturally declines with age. An animal study evaluated whether epitalon can restore melatonin secretion and normalize circadian rhythms of cortisol production in aged female rhesus monkeys [8]. The experimental group received 10 µg of epitalon intramuscularly, once daily for 10 days, while the control group received saline. epitalon administration resulted in: A three-fold increase in evening melatonin secretion (48 vs. 15 pg/ml, p < 0.001) Restoration of normal day-night variations of circadian cortisol rhythm Effects selective for aged animals only Metabolic regulation Age-related changes in mitochondria, nutrient sensing, and hormone signaling may underpin metabolic changes that result in insulin resistance and other related diseases. Epitalon works partly by addressing these mechanisms, according to a study in rhesus monkeys [9]. Seven young (6–8 years) and seven old (20–27 years) monkeys were administered epitalon intramuscularly (10 µg/day for 10 days). After administration, older monkeys had: Decreased basal glucose concentration Improved glucose clearance rate (p<0.01) Restored early-phase insulin secretion (320% vs. 198% control, p<0.05) Improved late-phase insulin dynamics Glucose tolerance improvements persisted for 1–2 months post-treatment, even after epitalon withdrawal.